Rheumatic manifestations of skin disease
- PMID: 19851110
- PMCID: PMC3081507
- DOI: 10.1097/BOR.0b013e328333b9e2
Rheumatic manifestations of skin disease
Abstract
Purpose of review: There is an increasing interest in improving the understanding of pathophysiology, outcome measures, and therapies of rheumatic skin disease. Increasingly, studies are using the skin as a primary endpoint for evaluating therapies. This will review the current state of the art for the most common rheumatic skin diseases.
Recent findings: A number of medications, including biologics such as tumor necrosis factor alpha and interferon, have been associated with onset of cutaneous lupus. The cutaneous lupus erythematosus area and severity index has been further validated and utilized in a number of studies. Smoking continues to be associated both with presence and refractoriness of cutaneous lupus erythematosus to therapy. There are several tools now available for evaluating the skin disease of dermatomyositis, but there is a need for new effective therapies. Measurement of skin disease in scleroderma continues to be a challenge, and there is a need for more effective therapies. Several studies show efficacy of intravenous iloprost for severe Raynaud's and skin ulcers, and of bosentan for digital ulcers.
Summary: The present review covers new outcome measures, treatments, and unusual manifestations of cutaneous lupus, dermatomyositis, scleroderma, and rheumatoid arthritis. There have been a number of new studies related to validation of disease activity measures, as well as their use in evaluation of new therapies for these conditions. Validated outcome measures are required to perform meaningful studies, and will facilitate organized epidemiologic, quality of life, and therapeutic studies.
Similar articles
-
International exchange on the clinical practice and research of rheumatic skin diseases: A report of the 5th International Conference of Cutaneous Lupus Erythematosus.J Dermatol. 2024 Jul;51(7):881-884. doi: 10.1111/1346-8138.17153. Epub 2024 Mar 7. J Dermatol. 2024. PMID: 38450816
-
Autoantibody recognition of distinctly modified forms of the U1-70-kd antigen is associated with different clinical disease manifestations.Arthritis Rheum. 2000 Apr;43(4):881-8. doi: 10.1002/1529-0131(200004)43:4<881::AID-ANR20>3.0.CO;2-G. Arthritis Rheum. 2000. PMID: 10765934
-
Collagen vascular diseases.Med Clin North Am. 1998 Nov;82(6):1217-37, v. doi: 10.1016/s0025-7125(05)70414-4. Med Clin North Am. 1998. PMID: 9889747 Review.
-
Cutaneous manifestations of selected rheumatologic diseases.Am Fam Physician. 1996 Apr;53(5):1625-36. Am Fam Physician. 1996. PMID: 8623690 Review.
-
The skin in autoimmune diseases-Unmet needs.Autoimmun Rev. 2016 Oct;15(10):948-54. doi: 10.1016/j.autrev.2016.07.013. Epub 2016 Jul 29. Autoimmun Rev. 2016. PMID: 27481041 Review.
Cited by
-
Development of Lupus Erythematosus Tumidus During the Course of Systemic Sclerosis.Cureus. 2021 Sep 17;13(9):e18064. doi: 10.7759/cureus.18064. eCollection 2021 Sep. Cureus. 2021. PMID: 34671535 Free PMC article.
-
Detrimental Effects of Endovascular Intervention in Active Rheumatoid Vasculitis.Vasc Specialist Int. 2018 Jun;34(2):39-43. doi: 10.5758/vsi.2018.34.2.39. Epub 2018 Jun 30. Vasc Specialist Int. 2018. PMID: 29984217 Free PMC article.
-
Arthropathy in Dermatology: A Comprehensive Review.Indian Dermatol Online J. 2017 Mar-Apr;8(2):79-93. doi: 10.4103/idoj.IDOJ_25_17. Indian Dermatol Online J. 2017. PMID: 28405546 Free PMC article. Review.
-
Connective tissue ulcers.J Tissue Viability. 2013 Nov;22(4):92-102. doi: 10.1016/j.jtv.2013.04.003. Epub 2013 Jun 10. J Tissue Viability. 2013. PMID: 23756459 Free PMC article.
-
Renal involvement in autoimmune connective tissue diseases.BMC Med. 2013 Apr 4;11:95. doi: 10.1186/1741-7015-11-95. BMC Med. 2013. PMID: 23557013 Free PMC article. Review.
References
-
- Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol. 1981;4:471. - PubMed
-
- Werth VP. Clinical Manifestations of Cutaneous Lupus Erythematosus. J Autoimmun. 2005;4:296. - PubMed
-
- Albrecht JA, Braverman IM, Callen JP, Connolly MK, Costner M, Fivenson D, Franks A, Jorizzo J, Lee LA, McCauliffe D, Sontheimer RD, Werth VP. Dermatology position paper on the revision of the 1982 ACR criteria for SLE. Lupus. 2004;13:839. - PubMed
-
- Yell JA, Mbuagbaw J, Burge SM. Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol. 1996;135:355. - PubMed
-
- Jessop S, Whitelaw D, Jordaan F. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2001:CD002954. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials